148 related articles for article (PubMed ID: 26997222)
21. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
[TBL] [Abstract][Full Text] [Related]
22. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study.
Guillem JG; Ruby JA; Leibold T; Akhurst TJ; Yeung HW; Gollub MJ; Ginsberg MS; Shia J; Suriawinata AA; Riedel ER; Mazumdar M; Saltz LB; Minsky BD; Nash GM; Paty PB; Temple LK; Weiser MR; Larson SM
Ann Surg; 2013 Aug; 258(2):289-95. PubMed ID: 23187748
[TBL] [Abstract][Full Text] [Related]
23. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
24. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?
Perez RO; Habr-Gama A; Pereira GV; Lynn PB; Alves PA; Proscurshim I; Rawet V; Gama-Rodrigues J
Colorectal Dis; 2012 Jun; 14(6):714-20. PubMed ID: 22568644
[TBL] [Abstract][Full Text] [Related]
25. Limited Role for Routine Restaging After Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
Caturegli I; Molin MD; Laird C; Molitoris JK; Bafford AC
J Surg Res; 2020 Dec; 256():317-327. PubMed ID: 32712447
[TBL] [Abstract][Full Text] [Related]
26. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
[No Abstract] [Full Text] [Related]
28. Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study.
Shaish H; Aukerman A; Vanguri R; Spinelli A; Armenta P; Jambawalikar S; Makkar J; Bentley-Hibbert S; Del Portillo A; Kiran R; Monti L; Bonifacio C; Kirienko M; Gardner KL; Schwartz L; Keller D
Eur Radiol; 2020 Nov; 30(11):6263-6273. PubMed ID: 32500192
[TBL] [Abstract][Full Text] [Related]
29. Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
De Felice F; Magnante AL; Musio D; Ciolina M; De Cecco CN; Rengo M; Laghi A; Tombolini V
Eur J Surg Oncol; 2017 Jul; 43(7):1324-1329. PubMed ID: 28363512
[TBL] [Abstract][Full Text] [Related]
30. Routine preoperative restaging CTs after neoadjuvant chemoradiation for locally advanced rectal cancer are low yield: a retrospective case study.
Davids JS; Alavi K; Andres Cervera-Servin J; Choi CS; Sturrock PR; Sweeney WB; Maykel JA
Int J Surg; 2014 Dec; 12(12):1295-9. PubMed ID: 25448648
[TBL] [Abstract][Full Text] [Related]
31. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
[TBL] [Abstract][Full Text] [Related]
32. MRI features and texture analysis for the early prediction of therapeutic response to neoadjuvant chemoradiotherapy and tumor recurrence of locally advanced rectal cancer.
Park H; Kim KA; Jung JH; Rhie J; Choi SY
Eur Radiol; 2020 Aug; 30(8):4201-4211. PubMed ID: 32270317
[TBL] [Abstract][Full Text] [Related]
33. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
[No Abstract] [Full Text] [Related]
34. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial.
Thompson HM; Omer DM; Lin S; Kim JK; Yuval JB; Verheij FS; Qin LX; Gollub MJ; Wu AJ; Lee M; Patil S; Hezel AF; Marcet JE; Cataldo PA; Polite BN; Herzig DO; Liska D; Oommen S; Friel CM; Ternent CA; Coveler AL; Hunt SR; Garcia-Aguilar J;
JAMA Netw Open; 2024 Jan; 7(1):e2350903. PubMed ID: 38194231
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
[TBL] [Abstract][Full Text] [Related]
36. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Edden Y; Wexner SD; Berho M
Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
[TBL] [Abstract][Full Text] [Related]
37. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
[TBL] [Abstract][Full Text] [Related]
38. Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging.
Perez RO; Habr-Gama A; São Julião GP; Lynn PB; Sabbagh C; Proscurshim I; Campos FG; Gama-Rodrigues J; Nahas SC; Buchpiguel CA
Tech Coloproctol; 2014 Aug; 18(8):699-708. PubMed ID: 24509716
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK
Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298
[TBL] [Abstract][Full Text] [Related]
40. Computed tomography with histological correlation for evaluating tumor regression of rectal carcinoma after preoperative chemoradiation therapy.
Lee CT; Chow NH; Liu YS; Lin SC; Lin PC; Wu YH; Lee JC; Tsai HM
Hepatogastroenterology; 2012; 59(120):2484-9. PubMed ID: 22497951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
